[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Louis S. Schmukler net worth and biography

Louis Schmukler Biography and Net Worth

EVP of Bristol-Myers Squibb

Louis S. Schmukler serves as Executive Vice President, President - Global Product Development and Supply of the Company. From 2011 to 2017 – President, Global Product Development and Supply 2017 to 2019 – Senior Vice President and President, Global Product Development and Supply 2019 to present – Executive Vice President and President, Global Product Development and Supply

What is Louis S. Schmukler's net worth?: The estimated net worth of Louis S. Schmukler is at least $1.86 million as of May 10th, 2021. Mr. Schmukler owns 31,956 shares of Bristol-Myers Squibb stock worth more than $1,862,396 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Schmukler may own. Learn More about Louis S. Schmukler's net worth.
How do I contact Louis S. Schmukler?: The corporate mailing address for Mr. Schmukler and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Louis S. Schmukler's contact information.
Has Louis S. Schmukler been buying or selling shares of Bristol-Myers Squibb?: Louis S. Schmukler has not been actively trading shares of Bristol-Myers Squibb during the last quarter. Most recently, Louis S. Schmukler sold 15,000 shares of the business's stock in a transaction on Monday, May 10th. The shares were sold at an average price of $65.25, for a transaction totalling $978,750.00. Following the completion of the sale, the executive vice president now directly owns 31,956 shares of the company's stock, valued at $2,085,129. Learn More on Louis S. Schmukler's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 6,901 shares worth more than $349,655.16. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 700 shares worth more than $38,934.00. The most recent insider tranaction occured on November, 4th when SVP Phil M Holzer sold 700 shares worth more than $38,934.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 11/4/2024.

Louis S. Schmukler Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/10/2021	Sell	15,000	$65.25	$978,750.00	31,956
5/19/2020	Sell	25,000	$62.68	$1,567,000.00	26,777
11/5/2019	Sell	25,000	$56.56	$1,414,000.00	31,963
3/17/2017	Sell	5,000	$56.49	$282,450.00	21,483
5/2/2016	Sell	22,218	$71.95	$1,598,585.10	21,971
3/16/2015	Sell	12,000	$66.96	$803,520.00
1/29/2015	Sell	5,250	$60.73	$318,832.50

Louis S. Schmukler Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $58.28

$57.47

$58.30

50 Day Range

MA: $53.26

$48.25

$59.82

2 Week Range

Now: $58.28

$39.35

$61.08

Volume

2,581,383 shs

Average Volume

14,373,831 shs

Market Capitalization

$118.20 billion

P/E Ratio

N/A

Dividend Yield

4.12%

Beta

0.44

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.